Genomic Diagnostic Could Prevent Chemotherapy in 40% of Women with HER2+ Breast Cancer

Nineteen Spanish hospitals have participated in a clinical trial published in the journal ‘The Lancet Oncology’ which shows that up to 40% of women with HER2+ breast cancer could avoid chemotherapy, thanks to a genomic test which analyses 50 genes.

The results of this study, were presented by the research group on breast cancer SOLTI, which has the support of the Spanish Society of Medical Oncology (SEOM), during one of the plenary sessions of the Breast Cancer Congress, held last December in San Antonio (United States).

To read more about this, please click here. (In Spanish)

Tagged with

Published on 27. February 2017 in News Spain